Cytosorbents Corporation

CytoSorbents Corporation is a publicly traded company (NasdaqCM: CTSO) located in Monmouth Junction, New Jersey.[1][2][3]

CytoSorbents Corporation
Traded asNASDAQ: CTSO
Russell 2000 Component
IndustryCritical care
Headquarters
Monmouth Junction, New Jersey
,
USA
ProductsCytoSorb
Number of employees
152

CytoSorbents sells a cytokine adsorbing column ("CytoSorb" which received CE mark approval in 2011.[4][5]) -- a blood purification technology based on porous polymer beads that act like sponges in an attempt to remove harmful substances from the blood.[6][7]

The use of hemoperfusion columns is generally limited to patients who are critically ill in high-resource counties, and they require a patient to be connected to a hemofiltration system such as dialysis or ECMO. A few similar products exist, including polymyxin B hemoperfusion columns (Toraymyxin), which failed to show significance in a clinical trial for sepsis[8].

CytoSorbents was awarded a $3.8 million contract by Defense Advanced Research Projects Agency (DARPA) for its “Dialysis-Like Therapeutics” program to treat sepsis by removing cytokines and pathogen-derived toxins.[9] The US Army awarded the Company a $1.15 million small-business innovation research contract to evaluate the technology in burn and trauma.[10]

References
  1. "CTSO: Summary for CYTOSORBENTS COR- Yahoo! Finance". YAHOO Finance. Retrieved 9 April 2014.
  2. "CTSO stock quote – CytoSorbents Corporation stock price – NASDAQ.com". NASDAQ. Retrieved 9 April 2014.
  3. "CTSO SEC Filings". YAHOO. Retrieved 9 April 2014.
  4. Crutcher, Patrick. "Closer Look: CytoSorbents' Surprise CE Mark Approval". BioMed Reports. Retrieved 1 April 2011.
  5. "With EU Regulatory Approval Gained CytoSorbents Corporation (OTCBB: CTSO) One Step Closer to Goal of FDA Regulatory Approval". OTC Equity. Retrieved 9 April 2014.
  6. Baum, Stephanie. "Blood purification device for ICU patients seeks to control cytokine storm". Med City News. Retrieved 2013-05-24.
  7. "Septic shock secondary to β-hemolytic streptococcus-induced necrotizing fasciitis treated with a novel cytokine adsorption therapy". The International Journal of Artificial Organs. Retrieved 6 May 2014.
  8. "Spectral Medical's Toraymyxin fails pivotal trial". MassDevice. Retrieved 2020-02-28.
  9. "DARPA Dialysis-Like-Therapeutic Program Awards $3.8M to CytoSorbents". Global BioDefense. Retrieved 9 April 2014.
  10. "CTSO Awarded Ph II U.S. Army Grant". Zacks. Retrieved 9 April 2014.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.